Estrogens, Conjugated

With ongoing shortages impacting estrogen therapy patches, Femring offers consistent access and a dual indication for women navigating multiple symptoms of menopause. EAST HANOVER, N.J., May 27, 2026 /PRNewswire/ -- Increasing demand for estrogen therapy coupled with a growing awareness and interest in the menopause market have led to supply disruptions with the estrogen patch. As women across the country continue to face frustration with hormone therapy patch shortages and inconsistent product availability, Femring is emerging as a readily available and accessible treatment option for those seeking a convenient transdermal alternative. Femring offers flexibility in treatment with two dosing strengths, as well as a 90-day dosing regimen, fitting into the busy active lifestyle of the modern menopausal woman. Femring, a prescription vaginal ring uniquely designed to deliver continuous systemic estrogen therapy through a convenient, long-acting vaginal ring replaced every 90 days. Femring is designed to support uninterrupted symptom relief without the variability patients may experience with other delivery methods. For women seeking an alternative to patches or daily therapies, Femring may offer a practical option that fits their lifestyle while helping maintain symptom control. "Women deserve confidence that their therapy will be available when they need it," said Dr. Rachel Rubin, MD. "As supply issues and treatment inconsistency continue to affect the market, Femring offers an established option physicians can prescribe, and patients can access. We also see this as an important opportunity to raise awareness about this dual-indication menopause treatment as Femring is the only FDA-approved product that treats both systemic issues like hot flashes as well as the genitourinary symptoms experienced in menopause." Healthcare providers are increasingly recognizing the importance of individualized treatment approaches in menopause care, particularly during periods of market disruption. Femring provides another evidence-based option to help support patient adherence and continuity of treatment. "Speaking with women who are navigating menopause today, they are sacrificing convenience in the middle of one of the busiest seasons of their lives," added AnneMarie Tipa, Millicent Pharma's Vice President of Sales and Marketing. "By increasing awareness of Femring, we hope to empower more women to have informed conversations with their healthcare providers about a 90-day treatment option that tackles multiple symptoms at once." Femring is indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause and moderate-to-severe vulvar and vaginal atrophy due to menopause. For more information about Femring, visit femring.com or speak with your healthcare provider. Please see the full Prescribing Information, including BOXED WARNING, Patient Information, and Instructions for Use . About Millicent Pharma Millicent Pharma is a leading specialty pharmaceutical company that offers multiple commercial products for women today, supporting its focus of advancing women's health through high quality and innovative solutions. More information can be found at About Femring Femring (estradiol acetate vaginal ring) is a prescription estrogen therapy designed to provide continuous systemic delivery of estradiol for up to 90 days. Femring is indicated for the treatment of moderate-to-severe vasomotor symptoms and vulvar and vaginal atrophy associated with menopause. Patients should discuss the benefits and risks of hormone therapy with their healthcare provider. Femring is a prescription vaginal ring that contains estradiol (an estrogen hormone). Femring should be removed after 90 days of continuous use. If you and your healthcare provider decide you should continue using Femring, a new ring can be inserted in your vagina. Femring is used after menopause to reduce moderate to severe hot flushes and treat moderate to severe menopausal changes in and around the vagina. Do not start using Femring if you have unusual vaginal bleeding; currently have or have had certain cancers, blood clots, or liver problems; had a stroke or heart attack; have been diagnosed with a bleeding disorder; are allergic to Femring or any of its ingredients; or think you might be pregnant. Before you use Femring, tell your healthcare provider if you have any unusual vaginal bleeding, have any problems with your vagina or cervix (lower end of your womb), have any other medical conditions, are going to have surgery or will be on bed rest, or are breastfeeding. Also tell your healthcare provider about all the medicines you take, including prescription and nonprescription medicines, vitamins and herbal supplements. Estrogens increase the risk of gallbladder disease. Discontinue estrogen if loss of vision, pancreatitis, or liver problems occur. If you take thyroid medication, consult your healthcare provider, as use of estrogens may change the amount needed. Serious, but less common side effects include heart attack, stroke, blood clots, dementia, breast cancer, cancer of the lining of the uterus (womb), cancer of the ovary, high blood pressure, high blood sugar, gallbladder disease, liver problems, changes in your thyroid hormone levels, and enlargement of benign tumors of the uterus ("fibroids"). Less serious, but common side effects include headache; breast tenderness or pain; irregular vaginal bleeding or spotting; stomach or abdominal cramps; bloating, nausea and vomiting; hair loss; fluid retention; vaginal yeast infection; and reactions from inserting Femring such as burning, irritation, and itching. Call your healthcare provider right away if you have any of the following warning signs, or any other unusual symptoms that concern you: new breast lumps, unusual vaginal bleeding, changes in vision or speech, sudden new severe headaches, severe pains in your chest or legs with or without shortness of breath, weakness and fatigue. For more information, talk with your healthcare provider. Media Contact: Andrea Tillman [email protected] SOURCE Millicent Pharma 21% more press release views with Request a Demo

Advanced Urology breaks the recurrent UTI cycle with a root-cause protocol. No more antibiotics. Prescribing another antibiotic without asking why the infection keeps recurring is not medicine. It is a delay. At Advanced Urology, we find the cause and we fix it.” — Jitesh Patel, MD ATLANTA, GA, UNITED STATES, April 20, 2026 / EINPresswire.com / -- Advanced Urology , metro Atlanta’s most innovative urology practice, today announced outcomes from the first 200 women treated under its comprehensive recurrent urinary tract infection (rUTI) protocol, reporting a marked reduction in antibiotic use, infection frequency, and patient-reported symptom burden. The results reflect what clinical leaders at the practice describe as a fundamentally different approach to one of the most common and most mismanaged conditions in medicine. Recurrent UTIs — defined as three or more infections in twelve months, or two in six — affect millions of American women each year and drive billions of dollars in healthcare spending. The standard approach has remained largely unchanged for decades: another culture, another antibiotic, another brief reprieve before the cycle begins again. Advanced Urology’s protocol rejects that model in favor of a root-cause evaluation that examines why infections keep occurring in the first place. Across the initial 200-patient cohort, the practice reports: A 45% reduction in antibiotic prescriptions per patient-year compared with the twelve months prior to enrollment 55% of patients reporting meaningful improvement in UTI-related bother and quality of life on validated symptom scoring A Different Premise “Recurrent UTIs are not a mystery — they are a symptom of underlying conditions that are not being addressed,” said Jitesh Patel, MD , Founder and President of Advanced Urology. “When we look at the whole patient — their metabolic health, their hormonal environment, their bladder function, their bacterial load — we almost always find treatable root causes. Our job is to find them and fix them, not to write the next antibiotic prescription and send the patient home to wait for the next infection.” The protocol is built around five coordinated interventions, selected and combined based on the specific drivers identified in each patient: Metabolic optimization — Elevated blood glucose feeds bacterial growth and increases the adherence of E. coli to the bladder wall. Every patient receives a thorough metabolic evaluation, with glucose control addressed as a foundational intervention. Topical vaginal estrogen — For women, restoring the hormonal environment of the urethral and vaginal tissues rebuilds the natural bacterial defense system. The 2025 AUA guideline strengthened its support for preventive vaginal estrogen in eligible women. Methenamine hippurate (Hiprex) — A urinary antiseptic that converts to bactericidal formaldehyde in acidic urine. Because it is not an antibiotic, bacterial resistance is not a meaningful concern. The 2025 AUA guideline formally includes methenamine hippurate as a prophylaxis option for women with recurrent UTIs. Clean intermittent catheterization — For selected patients, home-based CIC eliminates the residual urine and bacterial reservoir that sustain the cycle of infection. Daily bladder irrigation — A home-based sterile water flush that mechanically reduces bacterial load in the bladder without any antibiotic exposure. The Antibiotic Stewardship Imperative The 2025 American Urological Association guideline update on recurrent UTI places new emphasis on antimicrobial stewardship and a microbiome-aware approach to treatment, reflecting a maturing understanding that repeated antibiotic courses disturb microbial communities throughout the body and paradoxically make future infections more likely, more resistant, and harder to treat. “The data is unambiguous: repeated antibiotic courses are not a sustainable solution for recurrent UTIs,” said Vahan Kassabian, MD, Chief Physician Officer of Advanced Urology. “They drive resistance, disrupt the microbiome, and do nothing to address why infections keep occurring. Our 200-patient experience demonstrates that a coordinated, evidence-based, root-cause-focused protocol can break that cycle — and keep patients off antibiotics rather than putting them back on them.” A Path Forward for Patients Many of the women treated under the protocol had cycled through antibiotics for years — in some cases decades — before arriving at Advanced Urology. Most leave with a clear understanding of why their infections keep occurring and a concrete, individualized plan to stop them. “If you have been treated for three, five, ten, or twenty UTIs and nobody has asked you about your blood sugar, your estrogen levels, or whether you might benefit from a non-antibiotic suppression strategy, you have not yet received a complete evaluation,” Dr. Patel said. “You deserve one.” About Advanced Urology Advanced Urology is metro Atlanta’s largest urology practice, with 12 clinic locations and 6 ambulatory surgery centers across Georgia. The practice provides comprehensive urologic care for men and women, with specialized programs in recurrent UTI, BPH, overactive bladder, prostate cancer, kidney stones, low testosterone, and erectile dysfunction. To learn more or schedule a recurrent UTI consultation, visit advancedurology.com or call 404-586-4570. Jamil Mawani Advanced Urology email us here Visit us on social media: Instagram Facebook YouTube Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.